Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies : Episode 7
Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.
Video Player is loading.
EP: 1.Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
EP: 2.Selecting Patients with MM for Teclistamab and Optimal Sequencing
EP: 3.Mechanism of Action of Teclistamab in R/R MM and Data Updates
EP: 4.Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
EP: 5.Bispecific Antibodies in Development for the Treatment of R/R MM
EP: 6.Treatment with Teclistamab Following Progression on CAR-T in R/R MM
Now Viewing
EP: 7.Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
EP: 8.Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
EP: 9.The Development of Bispecifics-Based Combination Therapies in MM
EP: 10.Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
EP: 11.Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM
EP: 12.Recent Data on Non-BCMA Targeting Bispecifics in R/R MM
EP: 13.Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
Recent Videos
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Role of Bridging Therapy for CAR-T Patients
Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
Overview of Process of CAR-T Therapy
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
